Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8051 to 8100 of 8134 results

  1. Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]

    In development [GID-TA11047] Expected publication date: 21 August 2024

    Technology appraisal guidance
    In development

  2. Fertility problems: assessment and treatment

    In development [GID-NG10263] Expected publication date: 29 May 2025

    NICE guideline
    In development

  3. Palopegteriparatide for treating chronic hypoparathyroidism ID6380

    In development [GID-TA11454] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]

    In development [GID-TA11480] Expected publication date: 13 November 2024

    Technology appraisal guidance
    In development

  5. Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]

    Awaiting development [GID-TA10752] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 23 May 2024.

    Technology appraisal guidance
    In consultation

  7. Suspected sepsis: recognition, diagnosis and early management

    In development [GID-NG10412] Expected publication date: 13 August 2025

    NICE guideline
    In development

  8. Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]

    Awaiting development [GID-TA11536] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Depression

    All NICE products on depression. Includes any guidance and quality standards.

    Topic page

  10. Olorofim for treating invasive fungal infections in people 16 years and over TS ID 11983

      Status ...

    Technology appraisal guidance
    Topic selection

  11. Cabotegravir for preventing HIV-1 in adults and young people [ID6255]

    In development [GID-TA11304] Expected publication date: 13 November 2024

    Technology appraisal guidance
    In development

  12. Leadless cardiac pacemaker implantation for bradyarrhythmias

    Awaiting development [GID-IPG10340] Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  13. Maternal and child nutrition

    In development [GID-NG10191] Expected publication date: 13 November 2024

    NICE guideline
    In development

  14. Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (Partial review of TA688) [ID6376]

    In development [GID-TA11471] Expected publication date: 03 July 2024

    Technology appraisal guidance
    In development

  15. CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack

    In development [GID-DG10054] Expected publication date: 10 July 2024

    Diagnostics guidance
    In development

  16. Direct skeletal fixation of limb or digit prostheses using intraosseous transcutaneous implants

    In development [GID-IPG10351] Expected publication date: 13 November 2024

    Interventional procedures guidance
    In development

  17. Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353

    In development [GID-TA11394] Expected publication date: TBC

    Technology appraisal guidance
    In development

  18. Acute kidney injury: prevention, detection and management - Assessing risk factors for acute kidney injury in adults having iodine-based contrast media

    In development [GID-NG10410] Expected publication date: 16 October 2024

    NICE guideline
    In development

  19. Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer ID 6436

    Awaiting development [GID-TA11532] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  20. Marstacimab for treating severe haemophilia A or moderately severe to severe haemophilia B in people 12 years and over [ID6342]

    In development [GID-TA11397] Expected publication date: TBC

    Technology appraisal guidance
    In development

  21. Pembrolizumab with chemotherapy for treating HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma [ID4030]

    In development [GID-TA11039] Expected publication date: 21 August 2024

    Technology appraisal guidance
    In development

  22. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]

    In development [GID-TA11369] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  23. Exagamglogene autotemcel for treating sickle cell disease [ID4016]

    In development [GID-TA11249] Expected publication date: 17 July 2024

    Technology appraisal guidance
    In development

  24. Adrenal insufficiency: identification and management

    In development [GID-NG10237] Expected publication date: 28 August 2024

    NICE guideline
    In development

  25. Type 2 diabetes in adults: management (medicines update)

    In development [GID-NG10336] Expected publication date: 19 June 2025

    NICE guideline
    In development

  26. Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis

    Awaiting development [GID-IPG10392] Expected publication date: 05 February 2025

    Interventional procedures guidance
    Awaiting development

  27. Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]

    In development [GID-TA11288] Expected publication date: TBC

    Technology appraisal guidance
    In development

  28. Fosdenopterin for treating molybdenum cofactor deficiency type A [ID6264]

    In development [GID-HST10055] Expected publication date: 29 January 2025

    Highly specialised technologies guidance
    In development

  29. Gilteritinib for maintenance treatment of FLT3-mutation-positive acute myeloid leukaemia after stem cell transplant [ID6243]

    In development [GID-TA11255] Expected publication date: TBC

    Technology appraisal guidance
    In development

  30. Artificial intelligence (AI) technologies for assessing skin lesions referred on the urgent suspected cancer pathway

    In development [GID-HTE10047] Expected publication date: TBC

    Health technology evaluations
    In development

  31. Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6146

    Awaiting development [GID-TA11222] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  32. Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]

    Awaiting development [GID-TA11161] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  33. Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6428

    Awaiting development [GID-TA11538] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  34. Nemolizumab for treating moderate to severe atopic dermatitis in people aged 12 and over or prurigo nodularis in adults ID6221

    In development [GID-TA11183] Expected publication date: TBC

    Technology appraisal guidance
    In development

  35. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development [GID-TA11220] Expected publication date: TBC

    Technology appraisal guidance
    In development

  36. Efgartigimod for treating generalised myasthenia gravis [ID4003]

    In development [GID-TA10986] Expected publication date: 24 July 2024

    Technology appraisal guidance
    In development

  37. Unilateral MRI-guided focused ultrasound thalamotomy for moderate-to-severe tremor in Parkinson's disease

    Awaiting development [GID-IPG10375] Expected publication date: 12 December 2024

    Interventional procedures guidance
    Awaiting development

  38. Givinostat for treating Duchenne muscular dystrophy in people 6 years and over ID6323

    In development [GID-TA11373] Expected publication date: TBC

    Technology appraisal guidance
    In development

  39. MRI guided focused ultrasound subthalamotomy in parkinson's disease

    Awaiting development [GID-IPG10402] Expected publication date: 12 December 2024

    Interventional procedures guidance
    Awaiting development

  40. Depemokimab for treating chronic rhinosinusitis with nasal polyps TSID 12012

    Awaiting development [GID-TA11542] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  41. Sirolimus for treating angiofibroma from tuberous sclerosis complex in people 6 years and older [ID3990]

    In development [GID-TA10883] Expected publication date: 18 September 2024

    Technology appraisal guidance
    In development

  42. Urinary Tract Infection (recurrent): antimicrobial prescribing

    In development [GID-NG10422] Expected publication date: 13 November 2024

    NICE guideline
    In development

  43. Surgical correction of hallux valgus using minimal access techniques

    In development [GID-IPG10339] Expected publication date: 20 June 2024

    Interventional procedures guidance
    In development

  44. Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation [ID6198]

    In development [GID-TA11167] Expected publication date: 04 June 2024

    Technology appraisal guidance
    In development

  45. Drug eluting stents for treating coronary heart disease: late stage assessment

    In development [GID-HTE10039] Expected publication date: TBC

    Health technology evaluations
    In development

  46. Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over [ID5104]

    In development [GID-TA11006] Expected publication date: 29 May 2024

    Technology appraisal guidance
    In development

  47. Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [ID6327]

    In development [GID-TA11389] Expected publication date: 19 June 2024

    Technology appraisal guidance
    In development

  48. Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]

    In development [GID-TA11139] Expected publication date: TBC

    Technology appraisal guidance
    In development

  49. Cor-Knot for tying suture knots in valve surgery

      Status ...

    Medical technologies guidance
    Topic selection

  50. TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation

      Status ...

    Medical technologies guidance
    Topic selection